转移性透明细胞肾细胞癌的透明细胞A型和B型分子亚型:肿瘤异质性与侵袭性
研究纳入111例有原发灶和至少一个转移灶组织的转移性透明细胞肾细胞癌患者,分析ClearCode34基因并分型为ccA或ccB。转移瘤内异质性见于22%(95%CI 3-60%),同一患者纵向转移灶间异质性见于23%(95%CI 10-42%),配对原发与转移灶间异质性见于43%(95%CI 32-55%);转移灶亚型与转移部位、分级及肿瘤坏死显著相关。作者认为单样本分析转移灶可能足够,但原发灶不能作为转移灶的良好替代。
要点
- 转移性透明细胞肾细胞癌中约四分之一转移瘤存在瘤内ccA/ccB亚型异质性。
- 配对原发与转移灶亚型不一致率达43%,原发灶不是转移灶的良好替代。
- 转移灶亚型与转移部位、分级和肿瘤坏死显著相关。
核心结论
- 约四分之一的转移瘤显示瘤内异质性,纵向转移瘤间异质性率相似;配对原发与转移瘤亚型43%不一致,提示原发瘤不是转移瘤的良好替代。
研究设计与样本
- 研究纳入111例有原发肿瘤组织和至少一个转移灶组织的患者,对所有肿瘤分析ClearCode34基因,将原发和转移瘤分类为透明细胞A型(ccA)或B型(ccB)。
主要发现
- 转移瘤内ccA/ccB亚型异质性见于22%(95%CI 3-60%)。
- 同一患者纵向转移瘤间亚型不一致见于23%(95%CI 10-42%)。
- 配对原发与转移瘤间亚型不一致见于43%(95%CI 32-55%)。
- 转移瘤中ccA/ccB亚型与转移瘤位置、转移瘤分级和肿瘤坏死存在显著关联。
- 亚型与生存的关联在原发ccRCC肿瘤中得到验证。
临床怎么用
- 作者认为,对于生物标志物研究,只要研究设计中纳入病理学审查,分析每个转移瘤的单一样本可能足够。
- 作者认为,原发肿瘤不是转移肿瘤的良好替代。
局限性
- 本研究的局限性在于仅分析了同时接受肾切除术和转移灶切除术的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intratumor molecular heterogeneity has been reported for primary clear cell renal cell carcinoma (ccRCC) tumors; however, heterogeneity in metastatic ccRCC tumors has not been explored. OBJECTIVE: To evaluate intra- and intertumor molecular heterogeneity in resected metastatic ccRCC tumors. DESIGN, SETTING, AND PARTICIPANTS: We identified 111 patients who had tissue available from their primary tumor and at least one metastasis. ClearCode34 genes were analyzed for all tumors. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary and metastatic tumors were classified as clear cell type A (ccA) or B (ccB) subtypes. Logistic and Cox regression were used to evaluate associations with pathologic features and survival. RESULTS AND LIMITATIONS: Intratumor heterogeneity of ccA/ccB subtypes was observed in 22% (95% confidence interval [CI] 3-60%) of metastatic tumors. Subtype differed across longitudinal metastatic tumors from the same patient in 23% (95% CI 10-42%) of patients and across patient-matched primary and metastatic tumors in 43% (95% CI 32-55%) of patients. Association of subtype with survival was validated in primary ccRCC tumors. The ccA/ccB subtype in metastatic tumors was significantly associated with metastatic tumor location, metastatic tumor grade, and presence of tumor necrosis. A limitation of this study is that we only analyzed patients who had both a nephrectomy and metastasectomy. CONCLUSIONS: Approximately one quarter of metastatic tumors displayed intratumor heterogeneity; a similar rate of heterogeneity was observed across longitudinal metastatic tumors. Thus, for biomarker studies it is likely adequate to analyze a single sample per metastatic tumor provided that pathologic review is incorporated into the study design. Subtypes across patient-matched primary and metastatic tumors differed 43% of the time, suggesting that the primary tumor is not a good surrogate for the metastatic tumor. PATIENT SUMMARY: Primary and secondary/metastatic cancers of the kidney differed in nearly one half of ccRCC patients. The pattern of this relationship may affect tumor growth and the most suitable treatment.
引用
- Serie DJ, Joseph RW, Cheville JC, et al. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. Eur Urol. 2016. PMID: 27899233. doi:10.1016/j.eururo.2016.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。